Samuel L Cytryn, Ryan H Moy, Darren Cowzer, Ronak H Shah, Joanne F Chou, Smita S Joshi, Geoffrey Y Ku, Steven B Maron, Avni Desai, Jessica Yang, Ryan Sugarman, Devika Rao, Zoe Goldberg, Carmelina Charalambous, Maria Lapshina, Ariel Antoine, Fiona Socolow, Nikhil Trivedi, Marinela Capanu, Hans Gerdes, Mark A Schattner, Marc Simmons, Mario E Lacouture, Viktoriya Paroder, Laura H Tang, Jinru Shia, David H Ilson, David B Solit, Michael F Berger, Yelena Y Janjigian
BACKGROUND: The addition of nivolumab to chemotherapy improves survival in patients with advanced oesophagogastric (oesophageal, gastric, or gastro-oesophageal junction) adenocarcinoma; however, outcomes remain poor. We assessed the safety and activity of regorafenib in combination with nivolumab and chemotherapy in the first-line treatment of advanced oesophagogastric adenocarcinoma. METHODS: This investigator-initiated, single-arm, phase 2 trial in adult patients (aged ≥18 years) with previously untreated, HER2-negative, metastatic oesophagogastric adenocarcinoma was done at the Memorial Sloan Kettering Cancer Center (New York, NY, USA)...
October 2023: Lancet Oncology